The description of new potential therapeutic targets in KIT-negative GIST-like (KNGL), might lead to novel molecular targeted therapies, as it is applied nowadays in KIT/ PDGFRA-driven GISTs [5, 11]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.